Research programme: CD66 antigen inhibitors - cCAM Biotherapeutics

Drug Profile

Research programme: CD66 antigen inhibitors - cCAM Biotherapeutics

Alternative Names: CM-10; MRG 1

Latest Information Update: 19 Aug 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator cCAM Biotherapeutics
  • Class Monoclonal antibodies
  • Mechanism of Action CD66 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Malignant melanoma; Solid tumours

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Malignant-melanoma(Metastatic disease) in Israel (IV, Injection)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Solid-tumours in Israel (IV, Injection)
  • 01 Sep 2012 Preclinical trials in Malignant melanoma (metastatic disease) in Israel (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top